A prospective, clinical interventional, multicenter cohort study will be necessary to confirm the relationships between the levels of anti-gAChR Abs, serum biomarkers (including VEGF and endostatin), and autonomic function (including the severity of GI dysmotility in SSc) versus the outcomes of immunotherapies. The gene discussed is VEGFA; the disease is Gastrointestinal dysmotility.